Hyderabad, Telangana, India, November 2025 — Gunjan Singh has taken on the role of Chief Executive Officer – API Plus Business at Cohance Lifesciences, marking a strategic advancement in the company’s vision to build a globally competitive, innovation-led pharmaceutical enterprise. In this pivotal leadership role, he will spearhead the API Plus vertical, driving business expansion, portfolio growth, strategic partnerships, and operational excellence across international markets. His appointment reinforces Cohance Lifesciences’ commitment to strengthening its integrated API and formulations strategy while shaping a scalable and future-ready pharmaceutical ecosystem.
Since joining Cohance Lifesciences as Business Head – API and Formulations, Gunjan has led end-to-end P&L ownership for this business unit, guiding commercial strategy, global customer relationships, and product lifecycle enhancements across key markets. His ability to balance execution rigor with long-term vision has enabled Cohance to strengthen its market positioning and accelerate growth across its expanding API and formulations portfolio.
Prior to Cohance Lifesciences, Gunjan served as Vice President and Head – Mature Markets API (North America, South America, Europe) at Dr. Reddy’s Laboratories, where he oversaw the PSAI business across regulated markets. He also led product management, global strategy initiatives, and key account development across multiple business units—consistent with his reputation for operational excellence and sharp commercial insight.
Before Dr. Reddy’s, he played a transformative role as Chief Executive Officer at Wanbury Limited, driving the company to its highest-ever sales through renewed R&D focus, improved pricing strategies, and enhanced plant operations. His impactful tenure at Jubilant Pharma as Vice President & Business Head – API showcased his ability to manage full P&L responsibility, build global teams, and accelerate growth even amid external challenges.
Gunjan’s earlier experiences include nearly seven years at Piramal Enterprises Limited, where he held senior roles leading global BD, strategy, and commercial excellence across API, nutrition, and CDMO businesses. During this period, he earned the prestigious Chairman’s Award for creating significant enterprise value. His foundational years at Accenture, EY, and Larsen & Toubro further enriched his expertise in strategy, finance, and operations, shaping the versatile leadership profile he brings to Cohance Lifesciences today.
About Cohance Lifesciences
Cohance Lifesciences (formerly Suven Pharmaceuticals Limited) is an integrated, technology-driven global CDMO platform committed to advancing therapeutics for a healthier world. With a renewed identity that reflects collaboration and enhancement, Cohance partners with innovators globally to advance transformative scientific solutions. The organization continues to expand its capabilities in APIs, formulations, and specialty businesses while upholding its commitment to innovation, quality, and sustainable growth.
Read Also : When HR “Produces Nothing”: A Response to Jennifer Sey’s Anti-HR Vision
The Fine Balance: Navigating Work, Life, and Mental Wellbeing
Mind the Leadership Gap – From Learning to Real-World Impact
How the Adecco Group is empowering its employees for the future of work
